PubMed Health⌕ Search

Biomedical subjects

Georgia Montouris

Publications and source records attributed to Georgia Montouris.

9 recordsLinked to original sources

Reproductive and sexual dysfunction in men with epilepsy.

Disturbances of reproductive and sexual health are common in people with epilepsy. Their etiology is not well understood but appears to be multifactorial, and both epilepsy itself and drugs used to treat it are implicated. Physiologically, sex steroid hormone levels, the hypothalamic-pituitary axis, and testicular function can be affected in men with epilepsy. Psychosocial complications associated with epilepsy can also affect reproductive health and sexuality. Clinicians need to investigate such problems carefully, both because of their multifactorial nature and because patients and physicians alike may often fail to recognize or be reluctant to acknowledge them; in particular, patients whose epilepsy had its onset before puberty may lack subjective awareness of impairments of sexual response and function. Treatments for reproductive and sexual dysfunction in men with epilepsy have been inadequately studied. Modalities such as medications for erectile dysfunction and surgery may be useful. Therapy with exogenous testosterone and an aromatase inhibitor may be helpful for men with epilepsy and sexual dysfunction due to testosterone deficiency.

Anticonvulsants↗

Knowledge of women's issues and epilepsy (KOWIE-II): a survey of health care professionals.

Attendees of the American College of Physicians 2003 annual meeting were invited to complete a computerized version of the Knowledge of Women's Issues and Epilepsy (KOWIE-II) questionnaire. This 10-item survey includes items specific to issues that affect women with epilepsy (WWE), including hormone sensitive seizures, effects of antiepileptic drugs (AEDs) on oral contraception, bone health, sexual function, pregnancy, and breast-feeding. A total of 202 healthcare providers (HCP) responded to the survey, 92% of which identified themselves as physicians. Few understood the effects of endogenous steroid hormones on seizure threshold (24%) and that epilepsy is associated with an increased incidence of female sexual dysfunction (37%). Most knew that enzyme-inducing AEDs may reduce the efficacy of oral contraceptives (71%) and that certain AEDs are associated with bone disease (77%). The majority were aware that most WWE have healthy children (86%), that women do not need to discontinue AEDs during pregnancy (75%), and that the most appropriate AED during pregnancy is one that best addresses the patient's seizures. Fewer than half (47%) of participants knew that women taking AEDs could breast-feed safely. This sample of HCPs was not adequately informed about the unique issues affecting WWE. An aggressive educational effort is necessary to close the gaps in knowledge.

Adult↗

Safety of the newer antiepileptic drug oxcarbazepine during pregnancy.

OBJECTIVE: Seizure control in pregnant women with epilepsy is vital, as maternal seizures may have deleterious consequences. The treatment of pregnant women with epilepsy is, however, complicated by the teratogenicity of older antiepileptic drugs (AEDs). In this review, the safety of the newer AED oxcarbazepine during pregnancy is assessed based on published pregnancy outcome data. Other relevant safety issues, such as oxcarbazepine pharmacokinetics during pregnancy and the compatibility of oxcarbazepine treatment with breastfeeding, are also discussed. METHODS: Literature searches of the following databases were performed: MEDLINE, EMBASE, eNova, NOWIMA (an internal Novartis Germany database), Derwent Drug File, SciSearch and BIOSIS. Identified publications were examined for original data reporting rates of foetal malformation following maternal exposure to oxcarbazepine as monotherapy or adjunctive therapy. RESULTS: Relevant publications reporting data from the worldwide Novartis safety database and pregnancy registries or study centres in six countries were identified. A total of 248 pregnancies involving maternal exposure to oxcarbazepine monotherapy and 61 involving adjunctive therapy were reported. There were six malformations among the monotherapy group, equating to a malformation rate of 2.4% (6/248). The malformation rate reported in the general population is 2-4%. There were four malformations associated with oxcarbazepine adjunctive therapy, equating to a malformation rate of 6.6% (4/61). CONCLUSIONS: This literature review suggests that, compared with newborns in the general population, the newborns of women receiving oxcarbazepine monotherapy during pregnancy do not appear to show an increased risk for malformations. However, the number of pregnancies involving maternal exposure to oxcarbazepine identified by this review is not sufficient to draw definitive conclusions. Additional information from large-scale pregnancy registries is required to confirm the safety profile of oxcarbazepine as monotherapy or adjunctive therapy during pregnancy.

Abnormalities, Drug-Induced↗

The interictal dysphoric disorder: recognition, pathogenesis, and treatment of the major psychiatric disorder of epilepsy.

The unawareness of psychiatrists about the importance of epilepsy dates back half a century, when epilepsy became considered an ordinary neurologic disorder. Epileptic seizures, however, can be provoked in every human being. Epilepsy is an extraordinary disorder that, beyond its well-known neurologic complexities, tends to become complicated with a wide range of specific psychiatric changes; they occur on the establishment of a temporal-limbic focus of intermittent excessive neuronal excitatory activity that produces increasingly inhibitory responses. These changes are distinct from those related to the two major psychiatric spheres for which a genetic basis is established, i.e., the manic-depressive and schizophrenic disorders, and represent a genetic sphere of its own. Apart from more subtle personality changes and the serious late complications of interictal psychoses and suicidal episodes, the key psychiatric syndrome associated with epilepsy consists of the interictal dysphoric disorder, with its characteristic intermittent and pleomorphic symptomatology. This disorder was clearly identified about a century ago by Kraepelin, when he established a comprehensive basis for the modern classification of the psychiatric disorders, at a time when epilepsy represented an area of major interest to psychiatrists. A practical method of recognizing the dysphoric disorder is reported. The disorder tends to be very treatable by combining psychotropic (chiefly antidepressant) with antiepileptic medication. The variations in treatment approach required are discussed and illustrated by representative case studies. Psychiatrists must become familiar with the psychiatric aspects of epilepsy to be able to assist the neurologists who focus on the neural complexities of the illness. They also must become able to recognize, among their own patients, the presence of a subictal dysphoric disorder that requires the same treatment as the interictal dysphoric disorder; combined treatment with antidepressant and antiepileptic medication is likewise indicated for the premenstrual dysphoric disorder, a condition that appears to belong to the spectrum of epilepsy-related psychiatric disorders. Furthermore, they must learn how an ignored population in their care, epilepsy patients confined to state hospitals, can be properly treated. Of particular importance is the need for psychiatrists to become familiar with the role of the paroxysmal affects in the general human condition, with their basic conflict to be intermittently angry and irascible yet otherwise good-natured, helpful, and religious--a conflict that tends to be particularly accentuated among patients with the "Sacred Disease."

Adolescent↗

Safety of 25- and 50-mg capsules in the initiation of zonisamide therapy in patients with epilepsy: an uncontrolled, open-label study.

OBJECTIVE: This study was designed to assess the safety of 25- and 50-mg dosage strengths of zonisamide for initial titration in patients with epilepsy. RESEARCH DESIGN AND METHODS: This phase 3, multicenter, open-label, uncontrolled study conducted at 26 study sites in the United States included male and female patients with epilepsy >or= 12 years of age. After a screening visit, subjects began zonisamide therapy at a dosage depending on their body weight. Zonisamide was titrated to 100 mg/day. MAIN OUTCOME MEASURES: At the study's conclusion, information regarding adverse events (AEs) and body weight was recorded. RESULTS: One hundred forty-three subjects enrolled and received at least one zonisamide dose. Of these subjects, 125 reached at least the 100-mg dosage before terminating the study. Eighty-two subjects (57.3%) experienced at least one AE. Most commonly reported AEs included headache, somnolence, asthenia, rhinitis, nausea, and rash. No significant change in patient body weight was noted during the study (95% confidence interval: -0.1, 0.6). CONCLUSIONS: Study limitations include the open-label design and the lack of direct comparison between lower (25- and 50-mg) and higher (100-mg) starting dosages. Despite these limitations, the 25- and 50-mg zonisamide dosage formulations were well tolerated in this study.

Adult↗

Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry.

The objective of this study was to assess the safety of gabapentin (Neurontin) exposure in human pregnancy. Prospective and retrospective data concerning 51 fetuses, including 3 twin gestations, were collected from 39 women with epilepsy and other disorders exposed to gabapentin during pregnancy. Data were collected and evaluated about the 44 live births, including maternal demographics, diagnosis, treatment and complications, and fetal complications and outcomes. The results of this study showed that the rates of maternal complication, cesarean section, miscarriage, low birth weight, and malformation were less than or similar to those seen in the general population or among women with epilepsy. Gabapentin exposure during pregnancy did not lead to an increased risk for adverse maternal and fetal events in this study. However, because of the small number of patients examined in this study, additional data from more pregnancies and outcomes are needed.

Acetates↗

Suicide in epilepsy: psychopathology, pathogenesis, and prevention.

OBJECTIVE: Death by suicide among patients with epilepsy has found scant psychiatric attention, yet it may occur at the rate reported among patients with manic-depressive illness. We aim to clarify the psychopathology and pathogenesis of suicide in epilepsy and to document an effective method of prevention.METHOD: A total of 10,739 patients with epilepsy were seen at the Epi-Care Center in Memphis from 1987 to 1999. The patients with significant psychiatric complications were evaluated systematically and treated with an increasingly effective psychopharmacologic approach.RESULTS: Five suicides were registered during the 12-year period. All occurred in patients with longstanding complex partial seizures and dysphoric disorder a short time after full control of the seizures was achieved. During the last 8years of the 12-year period, more effective pharmacotherapy of the psychiatric complications of epilepsy was used (augmented antidepressant medication), and the two suicides that still occurred had eluded this treatment. Review of earlier series confirms that suicide tends to occur particularly among patients with chronic epilepsy who have obtained good control of their seizures; suicide may occur during interictal dysphoric episodes with or without psychotic features or in a state of postictal depression.CONCLUSIONS: Suppression of seizures in longstanding epilepsy may be associated with suicidal risk. The psychotoxic effect of predominant inhibitory mechanisms appears to be the crucial pathogenetic factor in all suicides. The number of suicides in our series is a fraction of that expected based on previous reports and indicates that prevention by psychopharmacologic treatment is available.

Journal Article↗

To the Editor.

Explore the source record for details and available documents.

Journal Article↗